Drug Database
Back to search

Poland· PL-100512976

Augtyro

A other protein kinase inhibitors product containing repotrectinibum, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 2 of our 19 countries.

ATC L01EX

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAugtyroATCL01EXREGISTER NO.PL-100512976PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about repotrectinibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Repotrectinibum is registered in 2 of 19 countries.

Countries holding a registration under ATC L01EX (other protein kinase inhibitors), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 1 of them publish a price we can compare per daily dose
Search repotrectinibum products by name

Repotrectinibum · ATC L01EX

2 / 19 countries

  • Canada
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Repotrectinibum
Manufacturer
Bristol-Myers Squibb Pharma EEIG
Country
Poland (PL)
ATC code
L01EX
ATC class
Other protein kinase inhibitors
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    04150192368863

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Repotrectinibum in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All repotrectinibum products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Augtyro
  • Liechtenstein · Augtyro
  • Norway · Augtyro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ede21e6f-4083-4f32-9eac-93e9a507fc68
GET /v1/drugs/ede21e6f-4083-4f32-9eac-93e9a507fc68?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "160 mg",
  "packaging": "Rpz ¦ EU/1/24/1883/003 ¦ 160398\n20 kaps.\n04150192368863 ¦ Rpz ¦ EU/1/24/1883/004 ¦ 160399\n60 kaps.\n¦ UR/Z/4c/193/26 - 04150192368863",
  "substance": "Repotrectinibum 160 mg",
  "common_name": "Repotrectinibum",
  "pl_product_id": "100512976",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about repotrectinibum.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console